Sue Rees

Innovation and the Future of Pharmacovigilance

Send us a text

Imagine stepping into the world of pharmacovigilance with Sue Rees, founder of Sue Rees Consultancy, who has graced the industry for over three decades. As we stroll down memory lane, we relive Sue's fascinating progression from her rookie days at Smith, Kline & French's adverse events department to her critical QPPV roles across the continents. We unravel the compelling narrative of how Brexit prompted Sue's entrepreneurial journey and her contributions to the education sector.
Together with Sue, we traverse through the contrasting paths taken by the FDA and the EMA, and delve into the divergent experiences of countries at varying stages of their PV journey. We also contemplate the ripple effects of the UK's EMA exit on its international reputation.
Tune in as we contemplate the future of safety in organizations and the potential role of AI in diminishing manual case processing. We investigate the heightened emphasis on safety brought forth by the COVID-19 pandemic and explore effective delegation of responsibility within organizations. Let's tap into Sue's wisdom on the emerging trends of data gathering and legislation, and how the evolving regulations are reshaping career roles. As we peer into the future, we'll consider how technology could revolutionize data gathering, allowing us to concentrate on the clinical and scientific aspects of legislation.

Capitole

1. Sue Rees (00:00:00)

2. Innovation and Future of Pharmacovigilance (00:00:16)

3. Divergence and Innovation in Regulations (00:10:31)

4. Training and Roles in Pharmaceutical Safety (00:24:54)

5. The Future of Safety in Organizations (00:37:25)

6. Future of Data Gathering and Legislation (00:46:51)